KEYNOTE-146: Lenvatinib Plus Pembrolizumab as Early-Line Treatment of Advanced Endometrial Cancer

May 29-31, 2020; Online at meetings.asco.org/am
Lenvatinib plus pembrolizumab showed promising efficacy as early-line treatment for patients with advanced endometrial cancer that is not MSI-H or dMMR in this post hoc analysis of KEYNOTE-146.
Format: Microsoft PowerPoint (.ppt)
File Size: 208 KB
Released: June 5, 2020

Acknowledgements

Provided by Clinical Care Options, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
GlaxoSmithKline
Merck Sharp & Dohme Corp.
Novartis Pharmaceuticals Corporation

Related Content

Drs Ritu Salani and Eva Y. Pan discuss optimal approaches to current treatment of patients with gynecologic cancers in this module from Clinical Care Options (CCO)

Eva Y. Pan, PharmD, BCOP Ritu Salani, MD, MBA Physicians: maximum of 1.25 AMA PRA Category 1 Credits Registered Nurses: 1.25 Nursing contact hours Pharmacists: 1.25 contact hours (0.125 CEUs) Released: May 13, 2022 Expired: May 12, 2023

Drs Ritu Salani and Eva Y. Pan discuss optimal approaches to current treatment of patients with gynecologic cancers in this module from Clinical Care Options (CCO)

Eva Y. Pan, PharmD, BCOP Ritu Salani, MD, MBA Released: May 13, 2022

Commentary on immunotherapy in endometrial cancer with a focus on older patients, from Clinical Care Options (CCO)

Domenica Lorusso, MD, PhD Released: April 29, 2022

Clinical commentary with Eloise Chapman-Davis, MD, FACOG, on healthcare equity in gynecologic cancers, from Clinical Care Options (CCO)

Eloise Chapman-Davis, MD, FACOG Released: March 1, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings